These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 8251614)
1. Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats (II). Harashima H; Midori Y; Ohshima S; Yachi K; Kikuchi H; Kiwada H Biopharm Drug Dispos; 1993 Oct; 14(7):595-608. PubMed ID: 8251614 [TBL] [Abstract][Full Text] [Related]
2. Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats: I. Harashima H; Ohshima S; Midori Y; Yachi K; Kikuchi H; Kiwada H Biopharm Drug Dispos; 1992 Apr; 13(3):155-70. PubMed ID: 1576324 [TBL] [Abstract][Full Text] [Related]
3. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. Ishida T; Atobe K; Wang X; Kiwada H J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355 [TBL] [Abstract][Full Text] [Related]
4. Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Arnold RD; Mager DE; Slack JE; Straubinger RM Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8856-65. PubMed ID: 16361575 [TBL] [Abstract][Full Text] [Related]
5. Enhanced tumor targeting of doxorubicin by ganglioside GM1-bearing long-circulating liposomes. Unezaki S; Maruyama K; Ishida O; Takahashi N; Iwatsuru M J Drug Target; 1993; 1(4):287-92. PubMed ID: 8069570 [TBL] [Abstract][Full Text] [Related]
6. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat. Storm G; van Hoesel QG; de Groot G; Kop W; Steerenberg PA; Hillen FC Cancer Chemother Pharmacol; 1989; 24(6):341-8. PubMed ID: 2791187 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. Gabizon A; Shiota R; Papahadjopoulos D J Natl Cancer Inst; 1989 Oct; 81(19):1484-8. PubMed ID: 2778836 [TBL] [Abstract][Full Text] [Related]
8. In vivo evaluation of doxorubicin carried with long circulating and remote loading proliposome. Junping W; Maitani Y; Takayama K; Nagai T Int J Pharm; 2000 Aug; 203(1-2):61-9. PubMed ID: 10967428 [TBL] [Abstract][Full Text] [Related]
9. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. Yokoe J; Sakuragi S; Yamamoto K; Teragaki T; Ogawara K; Higaki K; Katayama N; Kai T; Sato M; Kimura T Int J Pharm; 2008 Apr; 353(1-2):28-34. PubMed ID: 18082345 [TBL] [Abstract][Full Text] [Related]
10. In vitro tests to predict in vivo performance of liposomal dosage forms. Amselem S; Cohen R; Barenholz Y Chem Phys Lipids; 1993 Sep; 64(1-3):219-37. PubMed ID: 8242835 [TBL] [Abstract][Full Text] [Related]
11. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166 [TBL] [Abstract][Full Text] [Related]
12. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Charrois GJ; Allen TM Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619 [TBL] [Abstract][Full Text] [Related]
13. Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin. Evjen TJ; Hagtvet E; Nilssen EA; Brandl M; Fossheim SL Eur J Pharm Sci; 2011 Jul; 43(4):318-24. PubMed ID: 21620968 [TBL] [Abstract][Full Text] [Related]
14. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity. Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682 [TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Rahman A; Carmichael D; Harris M; Roh JK Cancer Res; 1986 May; 46(5):2295-9. PubMed ID: 3697976 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and antitumor effect of doxorubicin carried by stealth and remote loading proliposome. Wang JP; Maitani Y; Takayama K; Nagai T Pharm Res; 2000 Jul; 17(7):782-7. PubMed ID: 10990195 [TBL] [Abstract][Full Text] [Related]
17. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073 [TBL] [Abstract][Full Text] [Related]
18. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149 [TBL] [Abstract][Full Text] [Related]